Literature DB >> 33840064

Importance of Anatomical Efficacy for Disease Control in Neovascular AMD: An Expert Opinion.

Konstantinos Balaskas1, Winfried M Amoaku2, Tomas Cudrnak3, Louise M Downey4, Markus Groppe5, Sajjad Mahmood6, Hemal Mehta7, Quresh Mohamed8, Bushra Mushtaq9, Philip Severn10, Athanasios Vardarinos11, Yit C Yang12.   

Abstract

BACKGROUND: Neovascular age-related macular degeneration (nAMD) presents a significant treatment burden for patients, carers and medical retina services. However, significant debate remains regarding how best to manage nAMD when assessing disease activity by optical coherence tomography (OCT), and particularly the significance of different types of fluid and how the understanding of anatomical efficacy can influence treatment strategies. This article provides opinion on the practical implications of anatomical efficacy and significance of fluid in the management of nAMD and proposes recommendations for healthcare professionals (HCPs) to improve understanding and promote best practice to achieve disease control.
METHODS: An evidence-based review was performed and an expert panel debate from the Retina Outcomes Group (ROG), a forum of retinal specialists, provided insights and recommendations on the definition, role and practical implications of anatomical efficacy and the significance of fluid at the macula in the management of nAMD.
RESULTS: The ROG has developed recommendations for achieving disease control through a zero-tolerance approach to the presence of fluid in nAMD as patients who avoid fluctuations in fluid at the macula have better visual outcomes. Recommendations cover five key areas: service protocol, training, regimen, multidisciplinary teams and engagement. This approach facilitates more standardised protocol-based treatment strategies.
CONCLUSIONS: Targeting a fluid-free macula and aiming for disease control are essential to improve outcomes. As new therapies and technologies become available, drying the macula and maintaining disease control will become even more achievable. The outlined recommendations aim to promote best practice among HCPs and medical retina services to improve patient outcomes.

Entities:  

Keywords:  Anatomical efficacy; Disease control fluid; OCT; Stability

Year:  2021        PMID: 33840064     DOI: 10.1007/s40123-021-00342-5

Source DB:  PubMed          Journal:  Ophthalmol Ther


  31 in total

1.  Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen: FLUID Study 24-Month Results.

Authors:  Robyn H Guymer; Caroline M Markey; Ian L McAllister; Mark C Gillies; Alex P Hunyor; Jennifer J Arnold
Journal:  Ophthalmology       Date:  2018-11-29       Impact factor: 12.079

2.  Ranibizumab for neovascular age-related macular degeneration.

Authors:  Philip J Rosenfeld; David M Brown; Jeffrey S Heier; David S Boyer; Peter K Kaiser; Carol Y Chung; Robert Y Kim
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

3.  Association between CFH, CFB, ARMS2, SERPINF1, VEGFR1 and VEGF polymorphisms and anatomical and functional response to ranibizumab treatment in neovascular age-related macular degeneration.

Authors:  Estefania Cobos; Sergio Recalde; Jaouad Anter; Maria Hernandez-Sanchez; Carla Barreales; Leticia Olavarrieta; Alicia Valverde; Marta Suarez-Figueroa; Fernando Cruz; Maximino Abraldes; Julian Pérez-Pérez; Patricia Fernández-Robredo; Luis Arias; Alfredo García-Layana
Journal:  Acta Ophthalmol       Date:  2017-09-19       Impact factor: 3.761

4.  Anatomical measures as predictors of visual outcomes in ranibizumab-treated eyes with neovascular age-related macular degeneration.

Authors:  David M Brown; Lisa Tuomi; Howard Shapiro
Journal:  Retina       Date:  2013-01       Impact factor: 4.256

5.  Clinical classification of age-related macular degeneration.

Authors:  Frederick L Ferris; C P Wilkinson; Alan Bird; Usha Chakravarthy; Emily Chew; Karl Csaky; SriniVas R Sadda
Journal:  Ophthalmology       Date:  2013-01-16       Impact factor: 12.079

6.  Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.

Authors:  Laurent Kodjikian; Eric H Souied; Gérard Mimoun; Martine Mauget-Faÿsse; Francine Behar-Cohen; Evelyne Decullier; Laure Huot; Gilles Aulagner
Journal:  Ophthalmology       Date:  2013-08-02       Impact factor: 12.079

7.  Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1.

Authors:  Carl D Regillo; David M Brown; Prema Abraham; Huibin Yue; Tsontcho Ianchulev; Susan Schneider; Naveed Shams
Journal:  Am J Ophthalmol       Date:  2008-02       Impact factor: 5.258

8.  Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration.

Authors:  SriniVas R Sadda; Lisa L Tuomi; Beiying Ding; Anne E Fung; J Jill Hopkins
Journal:  Ophthalmology       Date:  2018-02-21       Impact factor: 12.079

9.  The estimated prevalence and incidence of late stage age related macular degeneration in the UK.

Authors:  Christopher G Owen; Zakariya Jarrar; Richard Wormald; Derek G Cook; Astrid E Fletcher; Alicja R Rudnicka
Journal:  Br J Ophthalmol       Date:  2012-02-13       Impact factor: 4.638

10.  Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group.

Authors:  Winfried Amoaku; Konstantinos Balaskas; Tomas Cudrnak; Louise Downey; Markus Groppe; Sajjad Mahmood; Hemal Mehta; Quresh Mohamed; Bushra Mushtaq; Philip Severn; Athanasios Vardarinos; Yit Yang; Saad Younis
Journal:  Clin Ophthalmol       Date:  2018-09-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.